Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ESSA Pharma Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
EPIX
Nasdaq
2830
www.essapharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ESSA Pharma Inc.
3 Promising US Penny Stocks With Market Caps Under $80M
- Jan 1st, 2025 8:08 pm
When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?
- Dec 21st, 2024 12:59 pm
ESSA Pharma: Fiscal Q4 Earnings Snapshot
- Dec 17th, 2024 12:17 pm
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
- Dec 17th, 2024 12:00 pm
ESSA Pharma And 2 Other US Penny Stocks To Watch
- Nov 11th, 2024 12:09 am
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials
- Nov 4th, 2024 1:14 pm
Sector Update: Health Care Stocks Rise Late Afternoon
- Nov 1st, 2024 7:59 pm
Top Midday Decliners
- Nov 1st, 2024 6:16 pm
ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment
- Nov 1st, 2024 12:14 pm
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- Nov 1st, 2024 12:57 am
ESSA Pharma Insiders Placed Bullish Bets Worth US$709.0k
- Oct 28th, 2024 12:01 pm
EPIX: Masofaniten Combination Therapy with Enzalutamide Increases rPFS; Increasing Valuation to $33 per Share…
- Sep 24th, 2024 11:10 am
ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans
- Sep 16th, 2024 10:03 am
ESSA Pharma Inc. (EPIX): Wall Street Analysts Recommend This Canadian Stock Right Now
- Sep 15th, 2024 1:53 am
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
- Sep 13th, 2024 9:19 pm
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
- Sep 11th, 2024 8:05 pm
EPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024…
- Aug 8th, 2024 12:30 pm
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
- Aug 5th, 2024 11:00 am
ESSA Pharma to Present at the JonesHealthcare Seaside Summit
- Jul 8th, 2024 8:05 pm
Scroll